NEXGEL, INC. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 17, 2026, details the completion of a strategic asset acquisition and a concurrent private placement financing. NEXGEL, INC. (Nasdaq: NXGL) finalized an exclusive license agreement for Celularity Inc.'s regenerative biomaterials portfolio and secured funding to support the transaction and general working capital.
Key Financial Metrics and Capital Structure
- Financing Proceeds: The Company raised $6,900,000 in gross proceeds through a private placement of convertible notes and warrants. Commitments exist to raise an additional $475,000 by April 24, 2026.
- Acquisition Consideration: Total consideration for the Celularity business is $13,300,000, structured as an $8,300,000 upfront cash payment and a $5,000,000 convertible promissory note (the "Celularity Note").
- Debt Instruments:
- Notes: $6,900,000 principal from investors plus $5,000,000 Celularity Note. Interest rate is 10% per annum, payable quarterly. Maturity is 18 months from issuance.
- Conversion Terms: Initial conversion price of $0.60 per share with full-ratchet anti-dilution protection. Automatic price reset to the lower of the current price or the 5-day VWAP occurs at 12 months and maturity.
- Warrants: 5,750,000 warrants issued to investors (50% of underlying shares) with an exercise price of $0.80 per share, expiring in 5 years.
- Liability Assumption: The Company assumed approximately $500,000 in sales representative obligations from Celularity, which were converted into Notes and Warrants on identical terms.
- Liquidity and Use of Proceeds: Proceeds are designated for business development, general working capital, and funding the upfront license fee to Celularity.
Material Changes and Transaction Terms
The filing reports the execution of Amendment No. 1 to the Asset Purchase and Exclusive License Agreement originally signed on March 6, 2026. Key modifications include:
- Consideration Adjustment: The deal structure was finalized to include the $8.3M cash and $5M note, removing previous holdback or deferred consideration mechanisms.
- Milestone Payment Revision: The first $2,500,000 milestone payment is now due upon the earlier of achieving $25,000,000 in Net Sales or 15 months post-closing (provided $15,000,000 in Net Sales is achieved by that date).
- Outside Date Extension: The transaction outside date was extended from April 15, 2026, to April 30, 2026.
- Remaining Milestones: Up to $17,500,000 in future milestone payments remains unchanged.
Outlook, Risks, and Contingencies
- Dilution Caps: Conversion and exercise are limited to prevent any holder from beneficially owning more than 4.99% of outstanding shares (adjustable to 9.99% with notice). The aggregate issuance is capped at 19.99% of outstanding shares unless stockholder approval is obtained.
- Stockholder Approval Requirement: The Company must seek stockholder approval for issuances exceeding the 19.99% cap within 60 days of closing, with additional meetings every 60 days if not approved.
- Default Provisions: Upon an Event of Default, interest accrues at 18% (or maximum legal rate), and the principal becomes due at 105% of the outstanding amount. Prepayment requires holder consent and incurs a 110% penalty.
- Registration Rights: The Company must file a registration statement for the resale of shares within 75 days and seek effectiveness within 150 days.
- Financial Reporting: Pro forma financial information and financial statements of the acquired business are not included in this filing but will be submitted via amendment within 71 days.
Investor Verification Checklist
- Verify the Company's ability to secure stockholder approval for the 19.99% exchange cap to avoid issuance restrictions.
- Confirm the cash balance available to fund the $8,300,000 upfront payment to Celularity immediately following the financing close.
- Review the full text of the Convertible Promissory Note (Exhibit 4.1) for specific definitions of "Event of Default" and anti-dilution triggers.
- Monitor the upcoming filing of pro forma financial information (due within 71 days) to assess the impact of the acquisition on the balance sheet.
- Check for the filing of the registration statement covering the resale of warrant and note shares within the 75-day window.